BlueRock Therapeutics LP

History

Year	Detail
2016	Bayer and Versant Ventures joined forces and launched stem cell therapy company BlueRock Therapeutics with $225 Million Series A financing.
2017	The company established a development and manufacturing site in the MaRS Discovery District of Toronto.
2017	BlueRock Therapeutics and Universal Cells Inc. collaborated to create induced pluripotent stem (iPS) cell lines useful for the manufacture of allogeneic cellular therapies.
2017	The company established a corporate headquarters in Cambridge, Massachusetts, to support rapid growth and development.
2018	The company established a research and development hub in New York City and collaborated with the Center for Stem Cell Biology at Memorial Sloan Kettering (MSK) Cancer Center.
2019	BlueRock Therapeutics partnered with Bruce Blazar, M.D., Regents Professor of Pediatrics, Division of Blood and Marrow Transplantation at the University of Minnesota, and Dr. Courtney Crane, Principal Investigator at the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Hospital.
2020	Ncardia and BlueRock Therapeutics partnered under an agreement allowing Bluerock to access Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
2021	The company entered a strategic research and development alliance with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for eye diseases.
2021	Senti Bio and BlueRock Therapeutics collaborated to develop gene circuit-engineered cell therapies for regenerative medicine.
2023	BlueRock Therapeutics and bit. Bio collaborated and option agreement for discovering and manufacturing regulatory T cell (Treg) based therapies.
2024	BlueRock Therapeutics and the Foundation Fighting Blindness collaborated to expand the Uni-Rare natural history study of patients with inherited retinal diseases.